Vivos Therapeutics Inc
NASDAQ:VVOS
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Vivos Therapeutics Inc
NASDAQ:VVOS
|
12.4m USD |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
96.7B USD |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
75B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
61.7B EUR |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
27.3B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.7B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
23B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.3B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.8B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
12.8B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Vivos Therapeutics Inc
Glance View
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). The company is headquartered in Highlands Ranch, Colorado and currently employs 158 full-time employees. The company went IPO on 2020-12-11. The firm is focused on the development and commercialization to dental practices of a patented oral appliance technology and related protocols called the Vivos System. The firm's Vivos System is a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for people with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The Company’s business model is focused on dentists, and the Company’s program to train dentists and offer them other value-added services in connection with their ordering and use of the Vivos System for patients is called the Vivos Integrated Practice (VIP) program. Its primary product used in the Vivos System is the mRNA appliance, a specifically designed, custom oral appliance that is worn primarily in the evening hours and overnight and is available for adults.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Vivos Therapeutics Inc is -98.8%, which is above its 3-year median of -99%.
Over the last 3 years, Vivos Therapeutics Inc’s Net Margin has increased from -152.7% to -98.8%. During this period, it reached a low of -152.7% on Aug 30, 2022 and a high of -74.1% on Dec 31, 2024.
